This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Brain cancer	Integrin β_1 (CD29)	<p><i>In vitro</i> and mouse studies suggest CD29 inhibitors could help treat Avastin bevacizumab-resistant glioblastoma multiforme (GBM). In cultures of Avastin-treated or Avastin-resistant primary GBM cells, CD29 expression was greater than that in untreated or bevacizumab-sensitive cells. In mice with Avastin-resistant orthotopic xenograft GBM tumors, an anti-CD29 antibody (OS2966) decreased tumor growth compared with an inactive control IgG. In mice with Avastin-sensitive xenograft GBM tumors, OS2966 plus low-dose Avastin decreased tumor growth compared with low-dose Avastin plus control IgG. Ongoing work by OncoSynergy Inc. includes testing OS2966 in models of recurrent GBM and pancreatic cancer.</p> <p>Roche and its Genentech Inc. and Chugai Pharmaceutical Co. Ltd. units market Avastin, a humanized mAb against VEGF, to treat brain, breast and colorectal cancers.</p> <p>SciBX 6(20); doi:10.1038/scibx.2013.484 Published online May 23, 2013</p>	Patented by The Regents of the University of California; licensed to OncoSynergy; available for partnering	<p>Carbonell, W.S. <i>et al. Cancer Res.</i>; published online May 3, 2013; doi:10.1158/0008-5472.CAN-13-0011</p> <p>Contact: W. Shawn Carbonell, University of California, San Francisco, Calif. e-mail: shawn@oncosynergy.com</p>